Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 549

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction

Open access
Redfield, Margaret M., Anstrom, Kevin J., Levine, James A., Koepp, Gabe A., Borlaug, Barry A., Chen, Horng H., LeWinter, Martin M., Joseph, Susan M., Shah, Sanjiv J., Semigran, Marc J., Felker, G. Michael, Cole, Robert T., Reeves, Gordon R., Tedford, Ryan J., Tang, W.H. Wilson, McNulty, Steven E., Velazquez, Eric J., Shah, Monica R., Braunwald, Eugene·2015·New England Journal of Medicine

Abstract

BACKGROUND: Nitrates are commonly prescribed to enhance activity tolerance in patients with heart failure and a preserved ejection fraction. We compared the effect of isosorbide mononitrate or placebo on daily activity in such patients. METHODS: In this multicenter, double-blind, crossover study, 110 patients with heart failure and a preserved ejection fraction were randomly assigned to a 6-week dose-escalation regimen of isosorbide mononitrate (from 30 mg to 60 mg to 120 mg once daily) or placebo, with subsequent crossover to the other group for 6 weeks. The primary end point was the daily activity level, quantified as the average daily accelerometer units during the 120-mg phase, as assessed by patient-worn accelerometers. Secondary end points included hours of activity per day during the 120-mg phase, daily accelerometer units during all three dose regimens, quality-of-life scores, 6-minute walk distance, and levels of N-terminal pro-brain natriuretic peptide (NT-proBNP). RESULTS: In the group receiving the 120-mg dose of isosorbide mononitrate, as compared with the placebo group, there was a nonsignificant trend toward lower daily activity (-381 accelerometer units; 95% confidence interval [CI], -780 to 17; P=0.06) and a significant decrease in hours of activity per day (-0.30 hours; 95% CI, -0.55 to -0.05; P=0.02). During all dose regimens, activity in the isosorbide mononitrate group was lower than that in the placebo group (-439 accelerometer units; 95% CI, -792 to -86; P=0.02). Activity levels decreased progressively and significantly with increased doses of isosorbide mononitrate (but not placebo). There were no significant between-group differences in the 6-minute walk distance, quality-of-life scores, or NT-proBNP levels. CONCLUSIONS: Patients with heart failure and a preserved ejection fraction who received isosorbide mononitrate were less active and did not have better quality of life or submaximal exercise capacity than did patients who received placebo. (Funded by the National Heart, Lung, and Blood Institute; ClinicalTrials.gov number, NCT02053493.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1510774

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 549

Metadata

Authors
Redfield, M. M., Anstrom, K. J., Levine, J. A., Koepp, G. A., Borlaug, B. A., Chen, H. H., LeWinter, M. M., Joseph, S. M., Shah, S. J., Semigran, M. J., Felker, G. M., Cole, R. T., Reeves, G. R., Tedford, R. J., Tang, W. H. W., McNulty, S. E., Velazquez, E. J., Shah, M. R., & Braunwald, E.
Venue
New England Journal of Medicine
Published
2015-12-10
Volume
373
Issue
24
Pages
2314-2324
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2213926659
Cited by
549
References
10
FWCI
34.80
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. https://app.cochat.ai/papers/10.1056/nejmoa1510774
The paper
Redfield, M. M., Anstrom, K. J., Levine, J. A., Koepp, G. A., Borlaug, B. A., Chen, H. H., LeWinter, M. M., Joseph, S. M., Shah, S. J., Semigran, M. J., Felker, G. M., Cole, R. T., Reeves, G. R., Tedford, R. J., Tang, W. H. W., McNulty, S. E., Velazquez, E. J., Shah, M. R., & Braunwald, E. (2015). Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1510774

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.